

# Tomoyuki Makino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8404274/publications.pdf>

Version: 2024-02-01

41  
papers

405  
citations

1040056

9  
h-index

839539

18  
g-index

42  
all docs

42  
docs citations

42  
times ranked

497  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor necrosis factor- $\alpha$ induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation. <i>Cancer Science</i> , 2018, 109, 1524-1531.	3.9	72
2	CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. <i>Cancer Science</i> , 2019, 110, 279-288.	3.9	40
3	Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis. <i>Cancers</i> , 2020, 12, 89.	3.7	33
4	CD44 motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. <i>Cancer Science</i> , 2018, 109, 724-731.	3.9	29
5	Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells. <i>Prostate</i> , 2019, 79, 468-479.	2.3	29
6	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. <i>Oncotarget</i> , 2018, 9, 16185-16196.	1.8	26
7	Anti-proliferative and anti-migratory properties of coffee diterpenes kahweol acetate and cafestol in human renal cancer cells. <i>Scientific Reports</i> , 2021, 11, 675.	3.3	16
8	Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 72-80.	2.3	15
9	Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment. <i>Biomedicines</i> , 2021, 9, 414.	3.2	12
10	Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital. <i>Anticancer Research</i> , 2019, 39, 2607-2614.	1.1	9
11	Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy. <i>In Vivo</i> , 2021, 35, 1703-1709.	1.3	9
12	A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells. <i>Prostate</i> , 2021, 81, 295-306.	2.3	7
13	The Impact of Hypertension on the Clinicopathological Outcome and Progression of Renal Cell Carcinoma. <i>Anticancer Research</i> , 2020, 40, 4087-4093.	1.1	7
14	Treatment Outcomes in Neuroendocrine Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 2167-2176.	1.1	7
15	Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 477-486.	1.1	6
16	Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer. <i>In Vivo</i> , 2021, 35, 1247-1252.	1.3	6
17	Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 4470.	3.7	6
18	Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor. <i>In Vivo</i> , 2018, 32, 899-903.	1.3	5

#	ARTICLE	IF	CITATIONS
19	High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma. <i>Anticancer Research</i> , 2019, 39, 375-380.	1.1	5
20	Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. <i>Anticancer Research</i> , 2018, 38, 2045-2055.	1.1	5
21	Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 770067.	2.8	5
22	Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute. <i>Anticancer Research</i> , 2015, 35, 1723-8.	1.1	5
23	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer. <i>Cancers</i> , 2022, 14, 1803.	3.7	5
24	Mucosa-associated lymphoid tissue lymphoma involving the kidney: a case report and review of the literature. <i>International Cancer Conference Journal</i> , 2016, 5, 82-89.	0.5	4
25	Changes in penile length after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy. <i>Andrology</i> , 2018, 6, 903-908.	3.5	4
26	Metastatic urachal cancer treated effectively with gemcitabine/cisplatin combination chemotherapy and radiotherapy: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 139-142.	1.0	4
27	Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity. <i>Japanese Journal of Radiology</i> , 2020, 38, 1197-1208.	2.4	4
28	A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age. <i>Asian Journal of Andrology</i> , 2021, 23, 36.	1.6	4
29	Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract. <i>Anticancer Research</i> , 2018, 38, 2241-2245.	1.1	4
30	Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 1065-1071.	1.1	4
31	Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy. <i>Prostate International</i> , 2016, 4, 152-155.	2.3	3
32	Examination of Necessity for Pelvic Drain Placement After Robot-assisted Radical Prostatectomy. <i>In Vivo</i> , 2021, 35, 2895-2899.	1.3	3
33	The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer. <i>Anticancer Research</i> , 2020, 40, 1141-1146.	1.1	3
34	Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	3
35	Reply to Comment on “Kadomoto, S. et al. Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis” • <i>Cancers</i> 2020 12, 89. <i>Cancers</i> , 2020, 12, 354.	3.7	2
36	The effectiveness of high-dose-rate brachytherapy with external beam radiotherapy for clinically locally advanced and node-positive prostate cancer: long-term results of a retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2310-2317.	2.2	2

#	ARTICLE	IF	CITATIONS
37	Metastatic Urothelial Carcinoma of the Prepuce and Glans Penis: Suspected Implantation of Non-Muscle-Invasive Bladder Cancer via Urine. Case Reports in Oncology, 2014, 7, 509-512.	0.7	1
38	An important step in establishing a treatment strategy for small renal masses of clear cell renal cell carcinoma based on the significance of adverse histopathologic features on tumor needle biopsy. Annals of Translational Medicine, 2019, 7, S374-S374.	1.7	1
39	Abstract 1968: Tumor necrosis factor- $\alpha$ upregulation of CCR7 induces prostate cancer cell migration in lymphatic metastasis. , 2019, , .		0
40	MP18-06â€fTUMOR-ASSOCIATED MACROPHAGES INDUCE MIGRATION OF RENAL CELL CARCINOMA CELLS VIA ACTIVATION OF THE CCL20-CCR6 AXIS. Journal of Urology, 2020, 203, e236-e237.	0.4	0
41	Abstract 1968: Tumor necrosis factor- $\alpha$ upregulation of CCR7 induces prostate cancer cell migration in lymphatic metastasis. , 2019, , .		0